Advertisement

Topics

Alexion Receives Positive CHMP Opinion for Soliris® (Eculizumab) for the Treatment of Patients ...

03:06 EDT 23 Jun 2017 | BioMedReports - Blog

Alexion Pharmaceuticals, Inc.
Media
Arne Naeveke, PhD, 475-230-3774
Executive Director, Product Communications
or
Investors
Elena Ridloff, CFA, 475-230-3601
Vice President, Investor Relations
or
Catherine Hu, 475-230-3599
Director, Investor Relations

Read more...

Original Article: Alexion Receives Positive CHMP Opinion for Soliris® (Eculizumab) for the Treatment of Patients ...

NEXT ARTICLE

More From BioPortfolio on "Alexion Receives Positive CHMP Opinion for Soliris® (Eculizumab) for the Treatment of Patients ..."

Advertisement
Quick Search
Advertisement
Advertisement